151 results
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146:e20193611.
Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
of care within the church health institutions participating in the project. It includes building the capacity of health workers and community
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
Percentage
31. Leverage ratio (item 26 divided by item 30)
26.6492%
a. Does your institution have a community bank leverage ratio (CBLR) framework
6-K
EX-99.1
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community. Of note, at Week 12, both doses
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
.
mPharma provides innovative services, such as vendor-managed inventory services, data analytics and primary care solutions for community pharmacies
6-K
EX-99.5
dq9um3 9whgea3s2y
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
rrnzjzyv ui24
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
EX-99.2
hk6fd2dvp 9acncvi
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.3
afcnc9o 8e811
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
nyvllq
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
tlo48z8c9
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.1
ta9hs9itrr 2b
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
59j6y6bm sd9k
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.2
9o93jhd
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
vq7ta
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.3
davx0 9d9svf
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
g2o2e0lax0qrcd
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
cdse5co tmgirdo6k9k1
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm
6-K
EX-99.1
4nn4mge5roouk5 gq
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
jqzq8j4rto oatdbucu1
22 Sep 22
CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
9:49am